Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning For HLA Identical Sibling Allogeneic HSCT In Myeloid Malignancies. Retrospective Analysis.

NCT01683123 is registered in ClinicalTrials.gov with Grupo Espanol de trasplantes hematopoyeticos y terapia celular as lead sponsor.

NCT NCT01683123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01683123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning For HLA Identical Sibling Allogeneic HSCT In Myeloid Malignancies. Retrospective Analysis.
Lead sponsor
Grupo Espanol de trasplantes hematopoyeticos y terapia celular
Phase
Observational
Overall status
Completed
Start date
July 31, 2007
Completion date
October 31, 2012
Enrollment
143 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome, myeloproliferative disorders